Dr. Matthew Katz reviews the study that compared neoadjuvant treatment with FOLFIRINOX versus gemcitabine/nab-paclitaxel for resectable pancreatic cancer.
Gina Harrison underwent molecular profiling of her pancreatic tumor, which led her to a clinical trial. Genetic testing showed her BRCA1 mutation was random and not inherited by her children.
Dr. Jennifer Knox is leading the NeoPancONE trial for a biomarker that indicates which patients will respond better to certain chemotherapy before surgery.
When you start pancreatic cancer treatment it seems like everyone is speaking a language you don't know. Here are 18 important words to help you along.